Preview

Current Pediatrics

Advanced search

EXPERIENCE OF TREATMENT OF JUVENILE ANKYLOSING SPONDYLITIS WITH EYES LESION WITH ADALIMUMAB

Abstract

This article presents a case report of juvenile ankylosing spondylitis and severe uveitis. A successful treatment with biological agent adalimumab was described. Administration of this medication induced the remission of uveitis, and it allowed surgical treatment of complicated cataract. Treatment of adalimumab resulted in increase of acuity of vision and improvement of quality of life.
Key words: children, juvenile ankylozing spondylitis, rheumatoid uveitis, adalimumab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(1):135-141)

About the Authors

E.I. Alexeeva
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


S.I. Valieva
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


T.M. Bzarova
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


A.O. Lisitsin
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


N.A. Karagulyan
Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Cassidy J., Petty R. Textbook of paediatric rheumatology, 2nd end. New York: Churchill Livigstone. 2002.

2. Никишина И.П. Ювенильный анкилозирующий спондилоартрит: клиника и особенности течения. Автореф. дис. ... канд. мед. наук. М. 1995. 20 с.

3. Лисицин А.О., Алексеева Е.И., Бзарова Т.М., и др. Опыт применения адалимумаба у больной юношеским полиартритом с поражением глаз. Вопросы современной педиатрии. 2008; 7 (5): 115–120.

4. Bombardieri S., Ruiz А.А., Fardellone P. et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF–antagonist therapy in clinical practice. Rheumatology Advance Access. Publ. May 15, 2007. doi:10.1093/rheumatology/kem091.

5. Nicas S.N., Voulgan P.V., Alamanos Y. et al. Efficacy and safety of switching from Infliximab to adalimumab a comparative controlled study. Ann. Rheum. Dis. 2006; 65: 257–260.

6. Bennett A.N., Peterson P., Zain A. et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology. 2005; 44: 1026–3101.

7. Bijl A.E., Breedveld F.C., Antoni C.E. et al. Adalimumab (HUMIRA) is effective in treating patients with rheumatoid arthritis who previously failed infliximab. Ann. Rheum. Dis. 2005; 64 (Suppl. 111): 428.

8. Wick M.C., Ernestam S., Lmdblad S. et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel) results from the STURE registry at Karohnska University Hospital Scand. J. Rheumatol. 2005; 3 (4): 353–358.

9. Brocq O., Albert C., Roux C. et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy experience with 18 patients. Joint. Bone Spine. 2004; 71: 601-603.

10. Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin. Rheumatol. 2008; 27 (8): 1021–1028.

11. Haibel H., Rudwaleit M., Listing J. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open label extension up to week fifty two. Arthritis Rheum. 2008; 58 (7): 1981–1991.

12. Dana M.R., Merayo-Lloves J., Schaumberg D.A. et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis–associated uveitis. Ophthalmology. 1997; 104: 236–244.

13. Foster C.S. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current Opin Ophthalmol. 2003; 14: 395–398.

14. BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89: 444–448.

15. Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of Juvenile Idiopathic Arthritis associated Uveitis – A pilot study. Abstract presented at: 8th Annual European League Against Rheumatism (EULAR 2007). June 13–16, 2007. Barcelona, Spain. Abstract THU0483.

16. Vazquez–Cobian L.B., Flynn T., Lehman T.J.A. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149: 572–575.

17. Tynjala P., Kotaniemi K., Lindahl P. et. al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. 2008; 47 (3): 339–344.

18. Heiligenhaus A., Horneff G., Greiner К. et al. Inhibitors of tumour necrosis factor alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheilkd. 2007; 224 (6): 526–531.

19. Foeldvari I., Nielsen S., Kummerle-Deschner J. et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis–associated uveitis refractory to second line agents: results of a multinational survey. Nat. Clin. Pract. Rheumatol. 2007; 11: 608–609.


Review

For citations:


Alexeeva E., Valieva S., Bzarova T., Lisitsin A., Karagulyan N. EXPERIENCE OF TREATMENT OF JUVENILE ANKYLOSING SPONDYLITIS WITH EYES LESION WITH ADALIMUMAB. Current Pediatrics. 2009;8(1):135-141.

Views: 519


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)